Business
Ernexa Therapeutics Provides Update on Operational Excellence and Performance
The company’s operating loss declined by 51% year-over-year, reflecting a laser focus on relentless execution and significant progress in expense reductionCAMBRIDGE, Mass., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today provided an update on its operational excellence and performance for the first half of 2025. The company reported its financial results in its Quarterly
About this update from Ernexa Therapeutics Inc.
[{"type":"image","alt":"Ernexa Therapeutics Inc.","displaySize":"","headline":null,"caption":"Ernexa Therapeutics Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":166,"url":"https://media.zenfs.com/en/globenewswire.com/5060d0692cdc61118022bf7e5069f69d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_oDYUSflXSfeQ8zZ8t_rmg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIzMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/5060d0692cdc61118022bf7e5069f69d","width":300,"height":166}},"lazy":false},{"type":"text","content":"The company’s operating loss declined by 51% year-over-year, reflecting a laser focus on relentless execution and significant progress in expense reduction","length":155,"tagName":"p"},{"type":"text","content":"CAMBRIDGE, Mass., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today provided an update on its operational excellence and performance for the first half of 2025. The company reported its financial results in its Quarterly Report on Form 10-Q for the period ending on June 30, 2025, filed with the Securities and Exchange Commission on August 13, 2025. The substantial year-over-year improvements were driven by focused execution and cost discipline as the company advances its lead cell therapy product, ERNA-101 for ovarian cancer, toward clinical studies, as well as further progressing ERNA-201 for autoimmune disease.","length":745,"tagName":"p","attribs":{}},{"type":"text","content":"Ernexa is a stronger company today due to the following operational milestones achieved during the first half of this year:","length":123,"tagName":"p","attribs":{}},{"type":"list","items":[{"val":[{"type":"text","content":"Operating loss decreased by $5.5 million, or 51%, from $10.7 million during the six months ending on June 30, 2024 to $5.2 million during the six months ending on June 30, 2025.","length":177,"tagName":"p"}]},{"val":[{"type":"text","content":"Total operating expenses decreased by $5.4 million, or 51%, from $10.6 million during the six months ending on June 30, 2024 to $5.2 million during the six months ending on June 30, 2025.","length":187,"tagName":"p"}]},{"val":[{"type":"text","content":"General and administrative expenses decreased by $5.4 million, or 66%, from $8.2 mill...